Please use this identifier to cite or link to this item:
https://t2-4.bsc.es/jspui/handle/123456789/71870| Title: | Dataset: Interleukin (IL)-1 blocking agents for the treatment of COVID-19 A living systematic review |
| Keywords: | IL1 COVID COVID 19 coronavirus Interleukin inhibitors IL-1 blockade Interleukin-1 Receptor Blockade canakinumab IL1 blocking agents IL1 Receptors anakinra |
| Publisher: | Zenodo |
| Description: | This dataset is used in the analyses reported in the review entitled "Interleukin (IL)-1 blocking agents for the treatment of COVID-19 A living systematic review" IL-1 blockers are beneficial in inflammation-associated pathologies, such as rheumatoid arthritis (Mertens 2009) and possibly also in the subgroup of patients with severe sepsis where the inflammasome pathway is involved (Shakoory 2016). Similar benefits were reported in children with secondary macrophage activation syndrome, including cases triggered by viral infections (Mehta 2020b). In this review we aimed to assess the effectiveness of IL-1 blocking agents compared to placebo, standard of care or no treatment on outcomes in patients with COVID-19. This review is part of a larger project: the COVID-NMA project. We set-up a platform (https://covid-nma.com) where all our results are made available and updated bi-weekly. |
| URI: | https://t2-4.bsc.es/jspui/handle/123456789/71870 https://t2-4.bsc.es/jspui/handle/123456789/71870 |
| Other Identifiers: | https://zenodo.org/record/5853927 10.5281/zenodo.5853927 oai:covid19data.eui.eu:t47mn-v3d70 https://covid19data.eui.eu/records/t47mn-v3d70 |
| Appears in Collections: | EUI |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.